CEO Sonny Hsiao (Acepodia)
Taiwan's Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells
What if researchers could take the antibody-drug conjugate model and apply it to off-the-shelf NK cell therapy? For the Taiwan-based biotech Acepodia, that’s the $47 million question.
Acepodia closed its Series B round Tuesday morning, hoping to build upon CEO Sonny Hsiao’s work from when he was a biologist at UC Berkeley. The biotech plans to use the funds to advance its lead program through the end of a Phase I trial and launch a Phase II study, as well as to get two other candidates into the clinic.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters